Dr. Dennis Slamon is a prominent researcher in the field of oncology, based at UCLA Health Jonsson Comprehensive Cancer Center. He is best known for his groundbreaking work in the development of the breast cancer drug Herceptin, which targets specific genetic alterations found in 30 percent of breast cancer patients. After medical school at the University of Chicago, Slamon completed his fellowship in Hematology/Oncology at UCLA. His research has significantly influenced treatment protocols for breast cancer, particularly in relation to the HER-2/neu gene, which is associated with aggressive forms of breast cancer. In 1998, the FDA approved Herceptin for use in treating advanced breast cancer, marking a noteworthy milestone in cancer therapeutics. Currently, Dr. Slamon continues to explore the effectiveness of Herceptin in newly diagnosed breast cancer patients and is involved in developing innovative treatments for women dealing with breast and ovarian cancers. His extensive publication record, including studies on treatment responses and biomarker research, underscores his influence and dedication in the field of cancer research.
UCLA Health Jonsson Comprehensive Cancer Center • Los Angeles, CA
Leading research initiatives and clinical trials within the comprehensive cancer program.
UCLA Health Jonsson Comprehensive Cancer Center • Los Angeles, CA
Overseeing surgical oncology practices and clinical research.